These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 10668854

  • 1. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans.
    Nakajima M, Yamagishi S, Yamamoto H, Yamamoto T, Kuroiwa Y, Yokoi T.
    Clin Pharmacol Ther; 2000 Jan; 67(1):57-69. PubMed ID: 10668854
    [Abstract] [Full Text] [Related]

  • 2. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
    Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H, Yamazaki H, Yamamoto T, Kuroiwa Y, Yokoi T.
    Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nicotine metabolism and CYP2A6 allele frequencies in Koreans.
    Kwon JT, Nakajima M, Chai S, Yom YK, Kim HK, Yamazaki H, Sohn DR, Yamamoto T, Kuroiwa Y, Yokoi T.
    Pharmacogenetics; 2001 Jun; 11(4):317-23. PubMed ID: 11434509
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
    Johnstone E, Benowitz N, Cargill A, Jacob R, Hinks L, Day I, Murphy M, Walton R.
    Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
    [Abstract] [Full Text] [Related]

  • 7. Effects of whole deletion of CYP2A6 on nicotine metabolism in humans.
    Zhang X, Ameno K, Ameno S, Kinoshita H, Kubota T, Kumihashi M, Mostofa J, Iwahashi K, Ijiri I.
    Drug Chem Toxicol; 2002 May; 25(2):203-13. PubMed ID: 12024803
    [Abstract] [Full Text] [Related]

  • 8. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted.
    Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, Katoh M, Yokoi T.
    Eur J Pharm Sci; 2004 Aug; 22(5):419-25. PubMed ID: 15265511
    [Abstract] [Full Text] [Related]

  • 9. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
    Benowitz NL, Swan GE, Jacob P, Lessov-Schlaggar CN, Tyndale RF.
    Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
    [Abstract] [Full Text] [Related]

  • 10. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
    Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, Katoh M, McLeod HL, Yokoi T.
    Clin Pharmacol Ther; 2004 Dec; 76(6):519-27. PubMed ID: 15592323
    [Abstract] [Full Text] [Related]

  • 11. Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6.
    Nakajima M, Kuroiwa Y, Yokoi T.
    Drug Metab Rev; 2002 Nov; 34(4):865-77. PubMed ID: 12487152
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism.
    Oscarson M.
    Drug Metab Dispos; 2001 Feb; 29(2):91-5. PubMed ID: 11159795
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application.
    Levi M, Dempsey DA, Benowitz NL, Sheiner LB.
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):23-34. PubMed ID: 17206525
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.